P53 in Differentiated Thyroid Cancer

Completed

• Conditions: Thyroid Neoplasms

• Registration Number: NCT01954134
• Lead Sponsor: Cumhuriyet University

Brief Summary

In clinical practise patients with negative radioiodine scan with positive tyhroglobulin is considered as radioiodine resistant or in another words in the process of dedifferentiation. The aim of the present study was to search a simple blood test that could lead to early identification of patients with dedifferentiation. In this respect, we investigate whether the serum level of anti-p53 antibody has the diagnostic value in the follow-up of patients with high levels of thyroglobulin (tg) and negative I-131 scan.

Detailed Description

In the present study enrolled were 171 patients with mean age of 47.7±13.5 yrs (range; 16-80yrs) and 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0±9.8 yrs). 134 (78.4%) patients were female and 37 (21.6%) patients were male.

Study Timeline

• Study Start: 2010-12
• Primary Completion: 2013-01
• Study Completion: 2013-01
• Status Verified: 2013-09
• Study First Submitted: 2013-09-11
• Study First Submitted QC: 2013-09-26
• Last Update Submitted: 2013-09-26
• Study First Posted: 2013-10-01
• Last Update Posted: 2013-10-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 199

Inclusion Criteria

• Patients who were diagnosed with DTC
• Treated with total and/or near-total thyroidectomy
• Referred for I-131 ablation therapy or low dose I-131 whole body scan (WBS)
• Between December 2010 and January 2013.

Exclusion Criteria

• Dose 131-I given in another hospital
• Radioiodine treatment more than one year after thyroidectomy.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
There was not any risk for patients.	with in the first 8-10 months after surgery

Trial Locations

Locations (1)

Cumhuriyet University, School of Medicine, Dept. of Nuclear Medicine; 🇹🇷 Sivas, Turkey